Nautilus Biotechnology Inc expected to post a loss of 15 cents a share - Earnings Preview

Nautilus Biotechnology

25/04/2025 14:25

Nautilus Biotechnology Inc NAUT.OQ NAUT.O is expected to show no change in quarterly revenue when it reports  results on April 29 for the period ending March 31 2025

​LSEG's mean analyst estimate for Nautilus Biotechnology Inc is for a loss of 15 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $1.75​, above​ its last closing price of $0.71. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.16
-0.16
-0.14
Beat
13.6
Sep. 30 2024
-0.16
-0.16
-0.13
Beat
21.2
Jun. 30 2024
-0.16
-0.16
-0.14
Beat
14.6​
Mar. 31 2024
-0.17
-0.16
-0.15
Beat
7.7
​​Dec. 31 2023
-0.13
-0.14
-0.14
Met
3.4
Sep. 30 2023
-0.17
-0.17
-0.13
Beat
22.4​
Jun. 30 2023
-0.14
-0.15
-0.13
Beat
13.3
Mar. 31 2023
-0.16
-0.17
-0.12
Beat
28

This summary was machine generated April 25 at 13:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)